QualityStocksNewsBreaks Archives - Page 412 of 1482

WednesdayNov 09, 2022 10:29 am

QualityStocksNewsBreaks — Cepton Inc. (NASDAQ: CPTN) Reports Financial Numbers, Business Updates for Q3 2022

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is reporting its third-quarter 2022 results. Highlights of the financial report include a 171% increase in product revenue, which totaled $1.8 million, and minimal development revenue coming in at $1.2 million. The company also reported third quarter 2022 GAAP net loss totaled $17.4 million compared to GAAP net loss of $7.9 million in the prior year period with Q3 2022 non-GAAP net loss reaching $13.2 million compared to non-GAAP net loss of $6.6 million in 2021. The report noted that full year 2022 revenue is still expected to…

TuesdayNov 08, 2022 1:09 pm

QualityStocksNewsBreaks – Knightscope Inc. (NASDAQ: KSCP) Inks New 22-Device Contract with Florida College

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has signed an agreement to deploy 22 K1 Blue Light Towers at a Florida college. According to the announcement, many schools are ill-equipped to address campus safety challenges because of staffing shortages and budget constraints. Knightscope’s proprietary tech and devices provide key solutions to their challenges. The new college contract includes the retrofitting of 13 emergency call systems and the replacement of older, hardwired towers at two separate locations. The Florida college will be leveraging Knightscope’s cellular and satellite communications with solar power to offer students, faculty and visitors…

TuesdayNov 08, 2022 12:55 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences 1st-Ever Study Evaluating DehydraTECH-CBD’s Effect on Diabetes

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that study program DIAB-A22-1 is expected to begin on schedule today. According to the announcement, this is Lexaria’s first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol (“CBD”) may potentially have therapeutic utility against diabetes. The company has evidenced the safety and efficacy of DehydraTECH-CBD in human hypertension studies. Strong connections exist between heart disease, hypertension and diabetes, with hypertension twice as frequent in diabetics and hypertensive patients at greater risk of developing diabetes. Diabetes, which prevents the body from making enough insulin and results in…

TuesdayNov 08, 2022 12:10 pm

QualityStocksNewsBreaks – FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Enters Assembly, Validation Stage of Its First Farm-Ready Demonstration System

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a Canadian-based, growth-stage company committed to providing commercially viable and sustainable, cradle-to-cradle, clean-energy solutions, is entering the final phase of assembling and validating its on-farm, containerized, green-ammonia production system. The company has announced that it is installing its first full-scale demonstration system on a crop farm in Manitoba; FuelPositive anticipates running the system as a pilot project on the 11,000-acre farm under all types of operating conditions to verify that it can to produce green ammonia that can be used as fertilizer. The company also plans on eventually using the green ammonia as fuel to…

MondayNov 07, 2022 1:49 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Targeted ‘Finish Line Is Within Sight’ as It Pursues Potential GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) has been developing drug candidates for treating primary and metastatic brain and central nervous system cancer. “Berubicin, the company’s lead drug candidate, is a novel anthracycline in an ongoing international trail in glioblastoma (“GBM”) treatment. The interim analysis data from this potentially pivotal trial is expected in mid-2023… Berubicin was the first [anthracycline] to provide scientific data which appears to demonstrate its ability to cross the blood-brain barrier and was designed with a molecular target of topoisomerase II enzymes responsible for cleaving and recombing double-stranded DNA during cellular replication,” a recent article explains. “Since the beginning…

MondayNov 07, 2022 1:30 pm

QualityStocksNewsBreaks – Hillcrest Energy Technologies Ltd.’s (CSE: HEAT) (OTCQB: HLRTF) Enhanced Solution Holds Potential to Simplify, Redefine EV Charging

Hillcrest (CSE: HEAT) (OTCQB: HLRTF), a company developing transformative power conversion technologies, has sought to introduce its proprietary solution into the global vehicle-to-grid technology space. “Hillcrest Energy Technologies has filed a patent for an enhanced powertrain solution, which offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefits of the enhanced powertrain solution are the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless and bidirectional charging across current and future power levels,” a recent article…

MondayNov 07, 2022 12:08 pm

QualityStocksNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Announces Q3-2022 Results, Continued Strengthening of Leading Position in Uranium, Rare Earth Elements

Energy Fuels (NYSE American: UUUU) (TSX: EFR) announced its financial results for the quarter ended Sept. 30, 2022. Among the highlights, the company reported a robust balance sheet with $122.3 million of working capital as of Sept. 30, 2022, including $77.1 million of cash and cash equivalents, $11.6 million of marketable securities, $27.3 million of inventory, and no short-term (or long-term) debt. The company’s product inventory has a value of $44.1 million at current commodity prices. “Energy Fuels continues to strengthen our U.S. market leading position in uranium and rare earth elements, which are both critical to the clean energy…

MondayNov 07, 2022 11:41 am

QualityStocksNewsBreaks — Cepton Technologies Inc. (NASDAQ: CPTN) Partner with Leading Entities to Complete Project Resulting in Enhanced Road Safety

Cepton Technologies (NASDAQ: CPTN), a Silicon Valley innovator of high-performance lidar solutions, has joined with two other leading companies to complete a proof-of-concept project confirming that an integrated system has the ability to warn drivers of unseen hazards ahead. The other two companies involved in the project, dubbed Periscope, are ALP.Lab GmbH, an Austria-based technology provider of autonomous vehicle testing solutions, and TE Connectivity, a world leader in sensors and connectors. According to the announcement, Periscope relies on lidar sensors strategically located at intersections to extend a driver’s field of view and alert them about a pedestrian approximately five seconds…

MondayNov 07, 2022 11:12 am

QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Featured in Cleantech and Climate Change Podcast

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, was featured in a new edition of the Cleantech and Climate Change Podcast issued by Investorideas.com, a global news source and leading investor resource covering clean technology and renewable energy stocks issues. Mullen’s Founder, Chairman and CEO David Michery joined the podcast to discuss recent news and milestones and lay out Mullen’s future plans for manufacturing and sales. During the interview, Michery goes into detail on the significance of Mullen’s acquisition and controlling interest in EV truck innovator, Bollinger Motors (the company’s first EV acquisition), and the purchase of ELMS…

MondayNov 07, 2022 10:11 am

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, was featured in a recent report published by Zacks Small-Cap Research. In the report, Zacks valued BVXV at $12.00/ADS. The publication reads, “On August 25, 2022, BiondVax Pharmaceuticals Ltd. (BVXV) announced financial results for the second quarter of 2022 and provided a business update. The COVID-19 NanoAb program is proceeding on schedule, with an inhalation proof-of-concept study with the anti-SARS-CoV-2 NanoAb in COVID-19 infected animals expected to begin by the end of 2022. Based on…

Site Search

Company Search

Category: QualityStocksNewsBreaks